D. Bradley Welling,
MD, PhD, FACS
Massachusetts Eye and Ear
Investigator
Harvard Medical School
Walter Augustus Lecompte Professor Walter Augustus Lecompte Professor of Otolaryngology–Head and Neck Surgery
About My Research
Dr. Bradley Welling’s clinical and research interests focus primarily on NF2-associated vestibular schwannomas and the hearing loss, disequilibrium and facial paralysis that may result from the disease.
In 1996, Dr. Welling and his collaborators published the promoter of the NF2 gene and documented genotype-phenotype correlations. This work was awarded the Edmund Prince Fowler Award from The Triological Society for the best basic science thesis. Later work using cDNA microarray analysis to identify involved pathways in tumor formation was awarded the Nicholas Torok Award from the American Neurotologic Society.
In conjunction with these studies, Dr. Welling leads five targeted clinical trials for NF2-related tumors based upon his in vitro work and the work of many others.
Additional research interests for Dr. Welling include the use of regenerative growth factors for the promotion of healing of tympanic membrane (TM) perforations, as well as the use of virtual simulation in otologic surgery training.
The utility of regenerative growth factors in healing TM perforations has been shown in vivo. If found to be successful, the approach could offer an alternative to surgical repair (and greatly reduce associated cost and surgical morbidity). Dr. Welling’s work in the area of otologic surgery training has led to a validated model for temporal bone dissection.
Education
BA, Chemistry, University of Utah
MD, University of Utah
PhD, Pathobiology, The Ohio State University
Postgraduate Training
Internship, General Surgery, University of Iowa Hospitals and Clinics
Residency, Otolaryngology–Head and Neck Surgery, University of Iowa Hospitals and Clinics
Fellowship, Otology, Neurotology, and Skull Base Surgery, The Ear Foundation, Vanderbilt University
Professional Memberships (select)
American Academy of Otolaryngology–Head and Neck Surgery
American Neurotology Society
Association for Research in Otolaryngology
Columbus Ophthalmological and Otolaryngological Society
American College of Surgeons
The Triological Society
The Politzer Society
American Otological Society
Combined Middle/Western Section of Triological Society
Middle Section of the Triological Society
Collegium Oto-rhino-laryngologicum Amicitiae Sacrum
Honors (select)
Edmund Prince Fowler Award, The Triological Society
Nicholas Torok Award, American Neurotology Society
Daiichi Clinical Scholar, American Academy of Otolaryngology–Head and Neck Surgery
Honor Award, American Academy of Otolaryngology–Head and Neck Surgery
Best Doctors in America
Who's Who in Executives and Professionals
Vice Presidential Citation, Middle Section of the Triological Society
America's Top Physicians
Presidential Citation, American Otological Society
Michael E. Glasscock, MD, Leadership Award, Glasscock Fellows Alumni Association
Top Doctor Award, Castle Connolly
William F. House Lecturer, American Neurotology Society
Vice Presidential Citation, Southern Section of the Triological Society
Editorial Roles (select)
Editorial Board, Otology & Neurotology
Editorial Review Panel Member, Otolaryngology–Head and Neck Surgery
Secretary-Treasurer, Otology & Neurotology
President, Otology & Neurotology
Associate Editor, Laryngoscope
Other Professional Roles/Advisory Boards (select)
Board of Directors, American Board of Otolaryngology
Board of Directors, American Otological Society
President, Board of Directors, Otology & Neurotology, Inc.
Publications powered by Harvard Catalyst Profiles
- An External Validation Study for Automated Segmentation of Vestibular Schwannoma. Otol Neurotol. 2024 Mar 01; 45(3):e193-e197.
- Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials. Clin Trials. 2024 Feb; 21(1):18-28.
- Surgical Considerations in Inner Ear Gene Therapy from Human Temporal Bone Anatomy. Laryngoscope. 2024 Jan 10.
- Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma. Sci Adv. 2023 11 10; 9(45):eadf7295.
- Immune Profiling of Secreted Factors from Human Vestibular Schwannoma Cells and Tumor-associated Macrophages. Laryngoscope. 2024 Mar; 134 Suppl 5:S1-S14.
- Association of Plasma Metabolomic Biomarkers With Persistent Tinnitus: A Population-Based Case-Control Study. JAMA Otolaryngol Head Neck Surg. 2023 05 01; 149(5):404-415.
- Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons. Otolaryngol Clin North Am. 2023 Jun; 56(3):543-556.
- Vestibular dysfunction in neurofibromatosis type 2-related schwannomatosis. Brain Commun. 2023; 5(2):fcad089.
- Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series. Curr Oncol. 2023 03 20; 30(3):3473-3483.
- Identification of Immune-Related Candidate Biomarkers in Plasma of Patients with Sporadic Vestibular Schwannoma: Candidate Plasma Biomarkers in Vestibular Schwannoma. bioRxiv. 2023 Jan 26.
- Labyrinthine Fluid Signal Intensity on T2-Weighted MR Imaging in Patients With Vestibular Schwannomas Undergoing Proton Radiotherapy: A Longitudinal Assessment. Otol Neurotol. 2023 02 01; 44(2):183-190.
- Association of Stapedotomy Volume and Patient Sex With Better Outcome. JAMA Otolaryngol Head Neck Surg. 2022 10 01; 148(10):985-986.
- Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev. 2022 Sep 08; 26:169-180.
- Imbalance and dizziness caused by unilateral vestibular schwannomas correlate with vestibulo-ocular reflex precision and bias. J Neurophysiol. 2022 02 01; 127(2):596-606.
- Direct SARS-CoV-2 infection of the human inner ear may underlie COVID-19-associated audiovestibular dysfunction. Commun Med (Lond). 2021; 1(1):44.
- Neurofibromatosis: Molecular Pathogenesis and Natural Compounds as Potential Treatments. Front Oncol. 2021; 11:698192.
- The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration. Hum Gene Ther. 2022 01; 33(1-2):61-75.
- Systematic and other reviews: Criteria and complexities. Am J Otolaryngol. 2021 Sep-Oct; 42(5):102957.
- Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope Investig Otolaryngol. 2021 Oct; 6(5):1008-1019.
- Pulmonary Embolism and Sigmoid Sinus Thrombosis After Translabyrinthine Vestibular Schwannoma Resection: A Retrospective Case Series. Ann Otol Rhinol Laryngol. 2022 Jun; 131(6):683-689.
- Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16(7):e0252048.
- [Systematic and other reviews: criteria and complexities]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Jul 07; 56(7):687-690.
- Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S64-S72.
- Idiopathic Sudden Sensorineural Hearing Loss: Speech Intelligibility Deficits Following Threshold Recovery. Ear Hear. 2021 July/Aug; 42(4):782-792.
- Systematic and other reviews: Criteria and complexities. Head Neck. 2021 07; 43(7):1979-1982.
- Systematic and Other Reviews: Criteria and Complexities. Am J Rhinol Allergy. 2021 Jul; 35(4):412-416.
- Systematic and other reviews: criteria and complexities. J Otolaryngol Head Neck Surg. 2021 07 01; 50(1):41.
- Systematic and Other Reviews: Criteria and Complexities. Ear Nose Throat J. 2021 Jul; 100(6):403-406.
- Systematic and other reviews: Criteria and complexities. World J Otorhinolaryngol Head Neck Surg. 2021 Jul; 7(3):236-239.
- Systematic and Other Reviews: Criteria and Complexities. J Neurol Surg B Skull Base. 2021 Jun; 82(3):273-276.
- Systematic and Other Reviews: Criteria and Complexities. Laryngoscope. 2021 07; 131(7):1443-1445.
- Systematic and Other Reviews: Criteria and Complexities. Ann Otol Rhinol Laryngol. 2021 07; 130(7):649-652.
- Systematic and other reviews: Criteria and complexities. Int J Pediatr Otorhinolaryngol. 2021 08; 147:110640.
- IMPROVING BARRIER DRAPES FOR THE MITIGATION OF AEROSOL AND PARTICULATE SPREAD DURING MASTOIDECTOMY. Otol Neurotol. 2021 02 01; 42(2):347-349.
- A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemother Pharmacol. 2021 05; 87(5):599-611.
- Consortium of Otolaryngology Journal Editors: Collegiality and Contributions. Otolaryngol Head Neck Surg. 2020 12; 163(6):1067-1069.
- New developments in neurofibromatosis type 2 and vestibular schwannoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa153.
- American Neurotology Society, American Otological Society, and American Academy of Otolaryngology - Head and Neck Foundation Guide to Enhance Otologic and Neurotologic Care During the COVID-19 Pandemic. Otol Neurotol. 2020 10; 41(9):1163-1174.
- Demonstration and Mitigation of Aerosol and Particle Dispersion During Mastoidectomy Relevant to the COVID-19 Era. Otol Neurotol. 2020 10; 41(9):1230-1239.
- Expanded use of teleservices in otology and neurotology in response to the COVID-19 (SARS-Cov-2) pandemic. Laryngoscope Investig Otolaryngol. 2020 Oct; 5(5):950-953.
- Considerations in Management of Acute Otitis Media in the COVID-19 Era. Ann Otol Rhinol Laryngol. 2021 May; 130(5):520-527.
- American Neurotology Society, American Otological Society, and American Academy of Otolaryngology - Head and Neck Foundation Guide to Enhance Otologic and Neurotologic Care During the COVID-19 Pandemic. Otol Neurotol. 2020 Aug 20.
- MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas. Front Cell Neurosci. 2020; 14:191.
- Aerosol Dispersion During Mastoidectomy and Custom Mitigation Strategies for Otologic Surgery in the COVID-19 Era. Otolaryngol Head Neck Surg. 2021 01; 164(1):67-73.
- Consortium of Otolaryngology Journal Editors: Collegiality and Contributions. Laryngoscope. 2020 06; 130(6):1357-1358.
- Consortium of Otolaryngology Journal Editors-Collegiality and Contributions. JAMA Otolaryngol Head Neck Surg. 2020 06 01; 146(6):521-522.
- Airborne Aerosol Generation During Endonasal Procedures in the Era of COVID-19: Risks and Recommendations. Otolaryngol Head Neck Surg. 2020 09; 163(3):465-470.
- Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. Int Forum Allergy Rhinol. 2020 Jul; 10(7):798-805.
- Topical fibroblast growth factor-2 for treatment of chronic tympanic membrane perforations. Laryngoscope Investig Otolaryngol. 2020 Aug; 5(4):657-664.
- Demonstration and mitigation of aerosol and particle dispersion during mastoidectomy relevant to the COVID-19 era. Otol Neurotol. 2020 May 08.
- Chronic Conductive Hearing Loss Is Associated With Speech Intelligibility Deficits in Patients With Normal Bone Conduction Thresholds. Ear Hear. 2020 May/Jun; 41(3):500-507.
- Consortium of Otolaryngology Journal Editors: Collegiality and contributions. Int Forum Allergy Rhinol. 2020 05; 10(5):698-699.
- Consortium of Otolaryngology Journal Editors: Collegiality and Contributions. Am J Rhinol Allergy. 2020 May; 34(3):321-323.
- Consortium of Otolaryngology Journal Editors: collegiality and contributions. J Laryngol Otol. 2020 May; 134(5):379-380.
- Providing health care to patients with hearing loss during COVID-19 and physical distancing. Laryngoscope Investig Otolaryngol. 2020 Jun; 5(3):396-398.
- Consortium of Otolaryngology Journal Editors: Collegiality and Contributions. J Voice. 2021 Mar; 35(2):170-171.
- Consortium of Otolaryngology Journal Editors: Collegiality and Contributions. Ear Nose Throat J. 2021 Sep; 100(5_suppl):396S-398S.
- Consortium of Otolaryngology Journal Editors: Collegiality and Contributions. Ann Otol Rhinol Laryngol. 2020 06; 129(6):533-535.
- Consortium of Otolaryngology Journal Editors: Collegiality and contributions. Int J Pediatr Otorhinolaryngol. 2020 07; 134:109959.
- Consortium of Otolaryngology Journal Editors: Collegiality and contributions. Am J Otolaryngol. 2020 Nov - Dec; 41(6):102430.
- The natural progression of low-frequency hearing loss in patients who meet hybrid implant system candidacy criteria. Laryngoscope. 2020 05; 130(5):1299-1303.
- A Tribute to David J. Lim, MD: Researcher, Mentor, Organizer, and Friend. Ann Otol Rhinol Laryngol. 2019 Jun; 128(6_suppl):6S-7S.
- Publisher Correction: Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Sci Rep. 2018 Nov 23; 8(1):17449.
- Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13(6):e0197350.
- Otogenic brain abscesses: A systematic review. Laryngoscope Investig Otolaryngol. 2018 Jun; 3(3):198-208.
- Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Sci Rep. 2018 04 03; 8(1):5437.
- Reflections on the Last 25 Years of the American Otological Society and Thoughts on its Future. Otol Neurotol. 2018 04; 39(4S Suppl 1):S81-S94.
- Open Access-Is There a Predator at the Door? JAMA Otolaryngol Head Neck Surg. 2018 Apr 01; 144(4):289-290.
- Open access: Is there a predator at the door? Laryngoscope. 2018 06; 128(6):1255-1256.
- Open Access: Is There a Predator at the Door? Otol Neurotol. 2018 03; 39(3):271-272.
- Open Access: Is There a Predator at the Door? Ann Otol Rhinol Laryngol. 2018 Mar; 127(3):137-138.
- Open access: is there a predator at the door? J Laryngol Otol. 2018 Mar; 132(3):189-190.
- Open Access: Is There a Predator at the Door? Otolaryngol Head Neck Surg. 2018 03; 158(3):401-402.
- Open Access: Is There a Predator at the Door? Laryngoscope. 2018 Feb 15.
- Open Access: Is There a Predator at the Door? OTO Open. 2018 Jan-Mar; 2(1):2473974X17752132.
- Open Access: Is There a Predator at the Door? J Neurol Surg B Skull Base. 2018 Apr; 79(2):115-116.
- Open access: is there a predator at the door? Int Forum Allergy Rhinol. 2018 02; 8(2):81-82.
- Open Access: Is There a Predator at the Door? J Voice. 2018 Jan; 32(1):1-2.
- Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol. 2018 01; 299(Pt B):299-307.
- Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget. 2017 May 09; 8(19):31666-31681.
- Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in vitro and in vivo. Sci Rep. 2016 11 02; 6:36215.
- Cortical Auditory Evoked Potentials to Evaluate Cochlear Implant Candidacy in an Ear With Long-standing Hearing Loss: A Case Report. Ann Otol Rhinol Laryngol. 2016 Oct; 125(10):858-61.
- Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas. Neuro Oncol. 2016 09; 18(9):1265-77.
- Editorial. Laryngoscope Investig Otolaryngol. 2016 Feb; 1(1):5.
- A new open access journal. Laryngoscope. 2015 Sep; 125(9):2001.
- Classics from the laryngoscope. Laryngoscope. 2015 May; 125(5):1031-2.
- Group I Paks as therapeutic targets in NF2-deficient meningioma. Oncotarget. 2015 Feb 10; 6(4):1981-94.
- Do adults with cochlear implants rely on different acoustic cues for phoneme perception than adults with normal hearing? J Speech Lang Hear Res. 2014 Apr 01; 57(2):566-82.
- Comparison of Long-term Quality-of-Life Outcomes in Vestibular Schwannoma Patients. Otolaryngol Head Neck Surg. 2014 06; 150(6):1024-32.
- Neurophysiology of spectrotemporal cue organization of spoken language in auditory memory. Brain Lang. 2014 Mar; 130:42-9.
- Detecting soft failures in pediatric cochlear implants: relating behavior to language outcomes. Otol Neurotol. 2013 Dec; 34(9):1648-55.
- Wound breakdown after middle cranial fossa craniotomy: an unusual complication after rhytidectomy. Laryngoscope. 2014 Feb; 124(2):554-7.
- Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide. Otol Neurotol. 2013 Oct; 34(8):1519-27.
- Minimal reporting standard for reporting hearing outcomes. Laryngoscope. 2013 Feb; 123(2):303.
- Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Res. 2013 Jan 15; 73(2):792-803.
- Three-dimensional segmented volumetric analysis of sporadic vestibular schwannomas: comparison of segmented and linear measurements. Otolaryngol Head Neck Surg. 2012 Oct; 147(4):737-43.
- Modification and comparison of minimally invasive cochleostomy techniques: A pilot study. Laryngoscope. 2012 May; 122(5):1142-7.
- Treatment of vestibular schwannoma cells with ErbB inhibitors. Otol Neurotol. 2012 Feb; 33(2):244-57.
- Virtual temporal bone dissection system: OSU virtual temporal bone system: development and testing. Laryngoscope. 2012 Mar; 122 Suppl 1:S1-12.
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012 Jan; 158A(1):24-41.
- Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope. 2012 Jan; 122(1):174-89.
- AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro Oncol. 2011 Sep; 13(9):983-99.
- Melatonin: can it stop the ringing? Ann Otol Rhinol Laryngol. 2011 Jul; 120(7):433-40.
- Creating a cross-institutional grading scale for temporal bone dissection. Laryngoscope. 2010 Jul; 120(7):1422-7.
- Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009 Aug 15; 15(16):5032-5039.
- Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol. 2009 May; 93(1):61-77.
- Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer. 2009 Jun; 45(9):1709-20.
- Molecular biology of vestibular schwannomas. Methods Mol Biol. 2009; 493:163-77.
- Gene expression analysis of human otosclerotic stapedial footplates. Hear Res. 2008 Jun; 240(1-2):80-6.
- Spinal myxopapillary ependymoma metastatic to bilateral internal auditory canals. Ann Otol Rhinol Laryngol. 2008 Feb; 117(2):98-102.
- Nerve of origin, tumor size, hearing preservation, and facial nerve outcomes in 359 vestibular schwannoma resections at a tertiary care academic center. Laryngoscope. 2007 Dec; 117(12):2087-92.
- Chondromyxoid fibroma of the temporal bone: case report and review of the literature. Ann Otol Rhinol Laryngol. 2007 Dec; 116(12):922-7.
- Molecular studies of vestibular schwannomas: a review. Curr Opin Otolaryngol Head Neck Surg. 2007 Oct; 15(5):341-6.
- Does packing the eustachian tube impact cerebrospinal fluid rhinorrhea rates in translabyrinthine vestibular schwannoma resections? Otol Neurotol. 2007 Oct; 28(7):934-8.
- Recurrence of isolated multiple myeloma in the skull base: a case report and review of the literature. Ear Nose Throat J. 2007 Sep; 86(9):555-60.
- Bilateral cerebellopontine angle metastatic melanoma: a case report. Ear Nose Throat J. 2007 Jul; 86(7):388-90.
- Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope. 2007 Jun; 117(6):1069-72.
- Leaving a lasting impression: ear mold impressions as middle ear foreign bodies. Ann Otol Rhinol Laryngol. 2006 Dec; 115(12):912-6.
- Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice. Laryngoscope. 2006 Nov; 116(11):2018-26.
- Regulation of the neurofibromatosis 2 gene promoter expression during embryonic development. Dev Dyn. 2006 Oct; 235(10):2771-85.
- Cyclin D(1) and D(3) expression in vestibular schwannomas. Laryngoscope. 2006 Mar; 116(3):423-6.
- The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otol Neurotol. 2006 Feb; 27(2):197-208.
- Current concepts in the evaluation and treatment of neurofibromatosis type II. Otolaryngol Clin North Am. 2005 Aug; 38(4):671-84, ix.
- Angiofibrolipoma of the ear canal. Laryngoscope. 2005 Aug; 115(8):1461-2.
- Facial nerve monitoring parameters as a predictor of postoperative facial nerve outcomes after vestibular schwannoma resection. Otol Neurotol. 2005 Jul; 26(4):728-32.
- Predictive factors in pediatric stapedectomy. Laryngoscope. 2003 Sep; 113(9):1515-9.
- cDNA microarray analysis of vestibular schwannomas. Otol Neurotol. 2002 Sep; 23(5):736-48.
- Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas. Laryngoscope. 2002 Sep; 112(9):1555-61.
- Virtual temporal bone dissection: an interactive surgical simulator. Otolaryngol Head Neck Surg. 2002 Jul; 127(1):79-83.
- Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics. 2002 Jan; 79(1):63-76.
Show More
Show Less
